NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CEO Michael Davidson sold 58,253 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $35.30, for a total transaction of $2,056,330.90. Following the sale, the chief executive officer owned 459,859 shares of the company's stock, valued at approximately $16,233,022.70. This represents a 11.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
NewAmsterdam Pharma Price Performance
NAMS stock opened at $34.28 on Friday. The firm has a market capitalization of $3.89 billion, a P/E ratio of -19.81 and a beta of 0.06. The business's 50-day moving average is $34.05 and its two-hundred day moving average is $32.88. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $42.00.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.23). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%. On average, analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the stock. Royal Bank Of Canada lifted their price target on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an "outperform" rating in a report on Wednesday, January 21st. Wall Street Zen downgraded shares of NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a research note on Saturday, February 21st. Leerink Partners reiterated an "outperform" rating and issued a $55.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. Finally, HC Wainwright upgraded NewAmsterdam Pharma to a "strong-buy" rating in a research note on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, NewAmsterdam Pharma presently has an average rating of "Moderate Buy" and an average price target of $46.55.
Read Our Latest Research Report on NewAmsterdam Pharma
Institutional Trading of NewAmsterdam Pharma
Institutional investors and hedge funds have recently modified their holdings of the company. Seven Fleet Capital Management LP acquired a new position in shares of NewAmsterdam Pharma in the 4th quarter worth approximately $140,000. Empowered Funds LLC acquired a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at about $85,000. XTX Topco Ltd grew its stake in shares of NewAmsterdam Pharma by 1,714.1% during the 4th quarter. XTX Topco Ltd now owns 137,492 shares of the company's stock worth $4,823,000 after acquiring an additional 129,913 shares in the last quarter. Virtus Investment Advisers LLC boosted its stake in shares of NewAmsterdam Pharma by 32.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 7,142 shares of the company's stock worth $251,000 after buying an additional 1,731 shares during the last quarter. Finally, Twinbeech Capital LP bought a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at about $961,000. 89.89% of the stock is currently owned by institutional investors.
NewAmsterdam Pharma Company Profile
(
Get Free Report)
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
